Capricor Therapeutics (CAPR) Tops Q4 EPS by 3c

Capricor Therapeutics (NASDAQ: CAPR) reported Q4 EPS of ($0.31), $0.03 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $9.59 thousand versus the consensus estimate of $10 thousand.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• KB Home (KBH) Tops Q3 EPS by 16c
• Sun Communities completes $1.03B sale of Park Holidays to Aermont
• Progress Software completes $400M acquisition of Domo's data platform